<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bolus injections of <z:chebi fb="0" ids="45652">succinylcholine</z:chebi> (1.5 mg/kg) significantly <z:hpo ids='HP_0002516'>increased intracranial pressure</z:hpo> (ICP) in cats under <z:mpath ids='MPATH_458'>normal</z:mpath> conditions from control levels of 8 +/- 1 mm Hg to 16 +/- 3 mm Hg (+/- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>, P less than 0.01), and in the presence of artificially increased ICP from control levels of 27 +/- 1 mm Hg to 47 +/- 4 mm Hg (P less than 0.01) </plain></SENT>
<SENT sid="1" pm="."><plain>These approximately 100% increases in ICP were accompanied by a transitory decrease in mean arterial pressure (approximately 10 sec), followed by a 15-20% increase (P less than 0.05) </plain></SENT>
<SENT sid="2" pm="."><plain>Pulmonary arterial pressure increased 20-30% (P less than 0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>These results, when considered in conjunction with results previously obtained in humans, suggest that <z:chebi fb="0" ids="45652">succinylcholine</z:chebi> may be contraindicated in neurosurgical patients </plain></SENT>
</text></document>